GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OS Therapies Inc (AMEX:OSTX) » Definitions » Buildings And Improvements

OSTX (OS Therapies) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is OS Therapies Buildings And Improvements?


OS Therapies Buildings And Improvements Historical Data

The historical data trend for OS Therapies's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OS Therapies Buildings And Improvements Chart

OS Therapies Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Buildings And Improvements
- - - -

OS Therapies Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OS Therapies Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


OS Therapies Business Description

Traded in Other Exchanges
N/A
Address
115 Pullman Crossing Road, Suite 103, Grasonville, MD, USA, 21638
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.